HIKAL Hikal Q2 FY25 results (Jul–Sep 2024) and concall
Hikal reported a strong Q2 FY25, driven by improved volume offtake in the Pharmaceutical business and stable raw material prices, leading to significant revenue and EBITDA growth. While the Crop Protection sector showed signs of stabilization, it continues to face pricing pressure. The company is cautiously optimistic about sustained recovery and is focused on new customer acquisition, project pipeline, and operational efficiencies across its divisions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 453 |
| EBITDA | 75 |
| Net profit | 18 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
